Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + TAS-102 (Suyuan) + irinotecan as second-line therapy for RAS wild-type metastatic colorectal cancer
ChiCTR2100052512Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab, trifluridine + tipiracil and irinotecan in colorectal cancer (CRC), colon adenocarcinoma and rectal adenocarcinoma, sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Progression-free survival. Started Nov 2021; status: recruiting.
02
Drugs
bevacizumabtrifluridine + tipiracilirinotecan
03
Conditions
colorectal cancer (CRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100052512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052512.